Europe
21 November 2025 The week exposed fractures in the UK's industry—but also unexpected reasons for optimism. Five themes dominated conversations about the direction of the country's life sciences sector.
20 November 2025
18 November 2025
14 November 2025
11 November 2025
11 November 2025
Latest Features
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Europe
In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger.
Biotechnology
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Biotechnology
Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.
Big Pharma
Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
More News
28 October 2025 The tech is being used to crunch thousands of documents in billion-dollar mediations and emerging as a valuable party at the table, finds Muireann Bolger.
22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
17 October 2025 A US Senate subcommittee hearing on patent eligibility reform has David Kappos, former USPTO director, believing that “there’s a better chance than ever” of a pending bill becoming law, finds Sarah Speight.
16 October 2025 The court rejected Novartis’s request for emergency measures against a Spanish importer after the pharma company failed to meet the test to enforce an injunction, the winning lawyers told LSIPR.
15 October 2025 The new addition by Latham & Watkins is a “distinguished practitioner” and marks another departure from Simmons & Simmons.
15 October 2025 Artificial intelligence requires vast amounts of data, but its true value now lies in accuracy and careful curation, finds Sarah Speight.
30 September 2025 A landmark decision sees the European Patent Office confirm that once all original appeals are withdrawn, third-party interveners cannot continue proceedings.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox